Source: http://www.google.es/patents/US8337711
Timestamp: 2017-12-15 12:08:32
Document Index: 631382053

Matched Legal Cases: ['Application No. 2007554191', 'Application No. 2007554191', 'Application No. 2007', 'Application No. 2007', 'Application No. 2007554191', 'Application No. 2007554191', 'Application No. 2007', 'Application No. 2007']

Patente US8337711 - System and process for separating a material - Google Patentes
Disclosed is a system to separate, enrich, and/or purify a cellular population from a biological tissue, such as a tissue sample. For example, an adipose tissue sample can be acquired and disrupted. The disrupted tissue sample can then be separated and purified. The separated components can include multipotent,...http://www.google.es/patents/US8337711?utm_source=gb-gplus-sharePatente US8337711 - System and process for separating a material
Número de publicación US8337711 B2
Número de solicitud US 12/395,085
También publicado como EP2254991A1, US8801586, US9719063, US20090221075, US20130196425, US20140349388, WO2009111338A1
Número de publicación 12395085, 395085, US 8337711 B2, US 8337711B2, US-B2-8337711, US8337711 B2, US8337711B2
Inventores Randel Dorian, Michael D. Leach, Richard W. Storrs, Jason Chavarria
Citas de patentes (570), Otras citas (174), Citada por (9), Clasificaciones (24), Eventos legales (4)
US 8337711 B2
disrupting the sample volume to obtain a sample particle in a selected particle size range different than a sample volume particle size range prior to the disruption of the sample volume;
applying a first centrifugal force to the sample particle in the first section of the separation container;
spinning the separation container around a central axis to apply the centrifugal force to the sample particle;
moving the sample particle along an interior wall of the first section of the separation container while spinning the separation container; and
transferring the selected cell fraction into the second section of the separation container while spinning the separation container.
obtaining the sample volume from a source body; and
applying the selected cell fraction to the source body.
removing the seal from between the first section of the separation container and the second section of the separation container upon application of an opening force due at least in part to the applied centrifugal force.
11. The method of claim 10, wherein applying the centrifugal force includes applying at least a first centrifugal force and a second opening centrifugal force, wherein the second opening centrifugal force includes the opening force;
wherein applying the second opening centrifugal force causes at least a portion of the selected cell fraction to exert a force on a lid that closes a passage between the first section to the second section to open the lid to allow the selected cell fraction to move from the first section to the second section allowing the collecting of the selected cell fraction.
flexing a portion of a lid to remove the seal from between the first section and the second section with the second opening centrifugal force.
moving a lid from a first lid position that is sealing the first section from the second section to a second lid position that is unsealing the first section from the second section.
collecting the selected cell fraction in a second section of the separation container includes moving the selected cell fraction to a sump; and
removing the selected cell fraction from the second section of the separation container includes applying a suction to the sump to remove the selected cell fraction.
15. A method of separating a selected cell fraction from a sample volume, comprising:
disrupting the sample volume to obtain a separable sample having a sample particle in a selected particle size range;
disposing the separable sample having the sample particle in a first section of a separation container having a first wall extending from a first bottom wall to an upper rim having an interior surface and an exterior surface;
applying a centrifugal force to the sample particle in the first section of the separation container to cause both (1) collecting the selected cell fraction in a collection section positioned near the upper rim and at least contacting the exterior surface of the first wall, the collection section having a second wall extending from a second bottom wall to the upper rim, and wherein the second bottom wall is nearer the upper rim than the first bottom wall and (2) moving a sealing section that seals a collection volume within the collection section when in a closed position to an open position by flexing a flexible section to allow the sealing section to move to the open position from the closed position; and
removing the selected cell fraction from the collection section of the separation container.
operating a drive motor to spin the separation container and the collection section simultaneously to apply the centrifugal force.
closing a housing to enclose all of the separation container, the collection section, the lid, the sealing section, the flexible section, and the drive motor.
placing a lid assembly extending over both the separation container and the collection section;
wherein in the closed position the sealing section selectively seals the collection volume from a container volume of the separation container;
wherein at a selected spin rate the applied centrifugal force the sealing section moves to the open position from the closed position;
applying a centrifugal force to the sample particle in the first section of the separation container to cause both (1) collecting the selected cell fraction in a collection section positioned near the upper rim and at least contacting the exterior surface of the first wall, the collection section having a second wall extending from a second bottom wall to the upper rim, and wherein the second bottom wall is nearer the upper rim than the first bottom wall and (2) moving a sealing section.
19. The method of claim 15, wherein disrupting the sample volume to obtain a separable sample having the sample particle in the selected particle size range includes forming the sample particle to have an average particle size in a range of about 0.1 mm to about 5 mm.
20. The method of claim 15, wherein disrupting the sample volume to obtain a separable sample having the sample particle in the selected particle size range includes forming the sample particle to have an average particle size in a range of about 0.5 mm to about 2 mm.
21. The method of claim 15, wherein disrupting the sample volume to obtain a separable sample having the sample particle in the selected particle size range includes moving the sample volume though a perforated member defining at least a through bore.
22. The method of claim 21, wherein moving the sample volume though a perforated member defining at least a through bore includes:
placing the sample volume in a sample containing volume having an end covered by the perforated member; and
moving a forcing member to force the sample volume through the perforated member to create the sample particle.
23. The method of claim 15, wherein removing the selected cell fraction from the collection section of the separation container includes:
drawing a vacuum within the collection section wherein a barrier wall defines a first end of the collection section on a first side of the barrier wall and a second end of the collection section on a second side of the barrier wall such that the barrier wall disrupts a complete annular well of the collection section;
connecting a withdrawal device to a passage defined through a housing that encloses the separation container and the collection section.
25. A method of separating a selected cell fraction from a sample volume, comprising:
forming a separable volume having a sample particle in a selected particle size range from the sample volume;
disposing the formed sample particle in a first section of a separation container;
applying a first centrifugal force to the sample particle in the first section of the separation container while the first section is sealed relative to a second section of the separation container to cause at least a portion of the selected cell fraction to move within the first section of the separation container;
applying a second centrifugal force to the sample particle in the first section of the separation container to cause a sealing member to move from a sealed position to an unsealed position;
applying a third centrifugal force to the sample particle in the first section of the separation container after causing the sealing member to move to the unsealed position to allow at least the portion of the selected cell fraction to move into the second section of the separation container; and
removing at least a portion of at least the portion of the selected cell fraction from the second section of the separation container.
26. The method of claim 25, wherein applying the centrifugal force includes spinning the separation container around a central axis which causes at least the selected cell fraction to move along an interior wall of the first section of the separation container and transfer at least the portion of the selected cell fraction into the second section of the separation container.
prior to applying the first centrifugal force, forming a seal between the first section of the separation container and the second section of the separation container with the sealing member.
28. The method of claim 27, wherein applying the first centrifugal force and applying the second centrifugal force are the same force at a first time and a second time, respectively.
29. The method of claim 28, wherein applying the second centrifugal force causes the seal member to move to the unsealed position.
30. The method of claim 29, wherein applying the second centrifugal force includes causing at least a portion of the selected cell fraction to exert a force on the sealing member to allow the selected cell fraction to move from the first section to the second section.
31. The method of claim 25, wherein applying at least the second centrifugal force includes flexing a portion of the sealing member to remove the seal from between the first section and the second section.
moving the selected cell fraction to a sump by ceasing the application of the first centrifugal force, ceasing the application of the second centrifugal force, and ceasing the application of the third centrifugal force.
mixing the at least one of the sample volume or the sample particle with citrate, a biologically acceptable acid, or EDTA prior to at least one of forming a separable volume, disposing the formed sample particle in a first section of a separation container, applying a first centrifugal force, applying a second centrifugal force, or applying a third centrifugal force.
35. The method of claim 25, wherein forming the separable volume having the sample particle in the selected particle size range includes forming the sample particle to have an average particle size in a range of about 0.5 mm to about 2 mm.
36. The method of claim 25, wherein forming the separable volume having the sample particle in the selected particle size range includes disrupting the sample volume with only a mechanical force applied to the sample volume to obtain the sample particle.
37. The method of claim 36, wherein disrupting the sample volume with only a mechanical force includes moving the sample volume though a perforated member defining at least a through bore.
38. The method of claim 37, wherein moving the sample volume though a perforated member defining at least a through bore includes:
FIG. 5 is a perspective view of a tissue disrupter, according to various embodiments;
Once the tissue has been prepared for purification, the tissue can be placed into a separation or purification device in block 30. Placing the tissue sample in the device in block 30 can include transferring the tissue cells and any additive materials previously added. It will be understood that additives need not be provided. The transfer of the prepared tissue to the separation device in block 30 can be performed in any appropriate manner. For example, the material can be transferred in a syringe (e.g. sterile syringe), a transfer container, a sterile syringe, or any appropriate technique. Various transport systems can include those disclosed in U.S. patent application Ser. No. 11/222,303, filed Sep. 8, 2005, now U.S. Pat. No. 7,766,900, commonly assigned, and incorporated herein by reference.
The selected cell fraction can then be separated in block 32. The separation of the selected cell fraction can occur according to various embodiments, including those discussed further herein. For example, the GPS™ separation system, sold by Biomet Inc. of Warsaw, Ind., USA can be used to separate the selected cell fraction from tissue. Exemplary buoy separation systems are disclosed in U.S. patent application Ser. No. 10/932,882, filed on Sep. 2, 2004, now U.S. patent application Ser. No. 7,374,678, incorporated herein by reference. The buoy or separation device can be designed with an appropriate density or specific gravity for stem cell separation from adipose tissue, or other appropriate separations. Further, separation devices can include those discussed further herein.
Again, the assembly of the buoy portion 286 and the isolator 288, or selected portions thereof, can include a tuned density or specific gravity to position the collection area 290 at a selected equilibrium position of a sample that is positioned within the tube 282. Also, an appropriate collection or extraction syringe or device 294 can be used to collect material from the tube 282. Selected separation tubes can include the GPS III ™ system sold by Biomet, Inc. of Warsaw, Ind., USA. Further exemplary buoy separation systems are disclosed in U.S. patent application Ser. No. 12/101,594, filed on Apr. 11, 2008, now U.S. Pat. No. 7,992,725, incorporated herein by reference.
US7806276 * 11 Abr 2008 5 Oct 2010 Hanuman, Llc Buoy suspension fractionation system
WO2009111338A1 * 27 Feb 2009 11 Sep 2009 Biomet Manufacturing Corp. A system and process for separating a material
11 "MarrowStim™ Concentration Kit Peripheral Arterial Disease (PAD) Study" brochure. Web. Jul. 2, 2009 http://www.biomet.com/patients/clinical—recruitment—padstudy.cfm.
12 "MarrowStim™ Concentration System," brochure. Biomet Biologics Jun. 15, 2008.
13 "Plasmax® Plasma Concentration System" brochure. (Jun. 15, 2008) Biomet® Biologics.
14 "Prosys PRP Kit," brochure Tozai Holdings, Inc. http://tozaiholdings.en.ec21.com/Prosys—PRP—Kit—5467051—5467061.html Printed from Web Aug. 24, 2011.
15 "Prosys PRP Kit," Tozai Holdings, Inc. EC21 Global B2B Marketplace http://www.ec21.com/product-details/Prosys-PRP-Kit—5467061.html Printed from Web Jul. 18, 2011.
16 "Sefar Solutions for the Healthcare Industry," brochure (2003) 9 pages Sefar Medifab®.
17 "ThermoGenesis Corp. to Supply Autologous Thrombin Kits to Biomet, Inc.," PR Newslink: http:/tinyurl.com/4h3up. (Apr. 5, 2005) http://www.noblood.org/press-releases/2128-thermogenesis-corp-supply-autologous-thrombin-kits-biomet-inc [web accessed Sep. 27, 2011].
18 "Trypsinization of Adherent Cells," (undated) 2 pages.
19 Anesthesiology, vol. 81, No. 4, pp. 1074-1077, Oct. 1994, Hiromasa Mitsuhata, M.D., et al., "An Anaphylactic Reaction to Topical Fibrin Glue".
20 Ann Thorac Surg, vol. 53, pp. 530-531, 1992, Mehmet C. Oz, M.D., et al., "Autologous Fibrin Glue From Intraoperatively Collected Platelet-Rich Plasma".
21 Ann Thorac Surg, vol. 56, pp. 387-389, 1993, Robert L. Quigley, M.D., et al., "Intraoperative Procurement of Autologous Fibrin Glue".
22 Badiavas, et al., "Treatment of Chronic Wounds With Bone Marrow-Derived Cells," (Reprinted) Arch Dermatol. 139:510-516 (Apr. 2003).
23 Bang, N.U., et al., "Plasma Protein Requirements for Human Platelet Aggregation" Ann. N.Y. Acad Sci, 201:280-299 (1972).
24 Berguer, R., R. L. Staerkel, E. E. Moore, F. A. Moore, W. B. Galloway, and M. B. Mockus. "Warning: fatal reaction to the use of fibrin glue in deep hepatic wounds. Case reports." J Trauma 31 (3 1991): 408-11.
25 Berruyer, M., J. Amiral, P. Ffrench, J. Belleville, O. Bastien, J. Clerc, A. Kassir, S. Estanove, and M. Dechavanne. "Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors," J Thorac. Cardiovasc Surg 105 (5 1993):892-7.
26 Biopolymers, vol. 27, pp. 763-774, 1988, Gerald Marx, "Mechanism of Fibrin Coagulation Based on Selective, Cation-Driven, Protofibral Association".
27 Brodke, et al., "Bone Grafts Prepared with Selective Cell Retention Technology Heal Canine Segmental Defects as Effectively as Autograft", SCR-Enriched Bone Crafts Heal Canine Segmental Defects, Journal of Orthopaedic Research (May 2006) pp. 857-866.
28 Casali, B., F. Rodeghiero, A. Tosetto, B. Palmieri, R. Immovilli, C. Ghedini, and P. Rivasi. "Fibrin glue from single-donation autologous plasmapheresis." Transfusion 32 (Jul. 1992): 641-3.
29 CLOTALYST(TM) Automatic Clotting Factor, Would you like to have an autologous thrombin for rapid clotting and haemostasis?, brochure, Biomet Biologics, Inc., Feb. 2007 (12 pages).
30 CLOTALYST™ Automatic Clotting Factor, Would you like to have an autologous thrombin for rapid clotting and haemostasis?, brochure, Biomet Biologics, Inc., Feb. 2007 (12 pages).
31 Collier, B.S. et al., "The pH Dependence of Quantitative Ristocetin-induced Platelet Aggregation: Theoretical and Practical Implications-A New Device for Maintenance of Platelet-Rich Plasma pH", Hematology Service, Clinical Pathology Department, Clinical Center, National Institutes of Health, Bethesda, MD. 20014, Blood, vol. 47, No. 5 (May), 1976.
32 Collier, B.S. et al., "The pH Dependence of Quantitative Ristocetin-induced Platelet Aggregation: Theoretical and Practical Implications—A New Device for Maintenance of Platelet-Rich Plasma pH", Hematology Service, Clinical Pathology Department, Clinical Center, National Institutes of Health, Bethesda, MD. 20014, Blood, vol. 47, No. 5 (May), 1976.
33 Connolly, "Injectable Bone Marrow Preparations to Stimulate Osteogenic Repair," Clinical Orthopaedics and Related Research 313:8-18 (1995).
34 Connolly, John, M.D., et al. "Development of an Osteogenic Bone-Marrow Preparation." The Journal of Bone and Joint Surgery, Incorporated. vol. 71-A, No. 5 (Jun. 1989) pp. 684-691.
35 Dallari, et al., "In Vivo Study on the Healing of Bone Defects Treated with Bone Marrow Stromal Cells, Platelet-Rich Plasma, and Freeze-Dried Bone Allografts, Alone and in Combination," Healing of Bone Defects, Journal of Orthopaedic Research (May 2006) pp. 877-888.
36 De Ugarte, et al., "Comparison of Multi-Lineage Cells from Human Adipose Tissue and Bone Marrow," Cells Tissues Organs 174:101-109 (2003).
37 De Ugarte, et al., "Differential Expression of Stem Cell Mobilization-Associated Molecules on Multi-Lineage Cells from Adipose Tissue and Bone Marrow," Immunology Letters 89:267-270 (2003).
38 DelRossi, A. J., A. C. Cemaianu, R. A.Vertrees, C. J. Wacker, S. J. Fuller, J. Cilley Jr., and W. A. Baldino. "Platelet-rich plasma reduces postoperative blood loss after cardiopulmonary bypass." J Thorac Cardiovasc Surg 100 (2 1990): 281-6.
39 DePalma, L., et al., "The preparation of fibrinogen concentrate for use as fibrin glue by four different methods." Transfusion (1993) vol. 33, No. 9; pp. 717-720.
40 DeUgarte, M.D., Daniel A., et al., "Future of Fat as Raw Material for Tissue Regeneration," (Feb. 2003) pp. 215-219, Lippincott Williams & Wilkins, Inc.
41 DeUgarte, M.D., Daniel A., et al., "Future of Fat as Raw Material for Tissue Regneration," (2007) pp. 215-219, Lippincott Williams & Wilkins, Inc.
42 DiMuzio, Paul et al., "Development of a Tissue-Engineered Bypass Graft Seeded with Stem Cells," Vasucular, vol. 14, No. 6, (2006) pp. 338-342, BC Decker, Inc.
43 Drug Intelligence and Clinical Pharmacy, vol. 22, pp. 946-952, Dec. 1988, Dennis F. Thompson, et al., "Fibrin Glue: A Review of Its Preparation, Efficacy, and Adverse Effects as a Topical Hemostat".
44 Edlich, Richard F., George T. Rodeheaver, and John G. Thacker. "Surgical Devices in Wound Healing Management." In Wound Healing: Biochemical & Clinical Aspects,ed. I. Kelman Cohen, Robert F. Diegelmann, and William J. Lindblad. 581-600. 1st ed., vol. Philadelphia: W.B. Saunders Company, 1992).
45 Eppley, et al., "Platelet Quantification and Growth Factor Analysis from Platelet-Rich Plasma: Implications for Wound Healing," Plastic and Reconstructive Surgery, 114(6):1502-1508 (Nov. 2004).
46 Epstein, G. H., R. A. Weisman, S. Zwillenberg, and A. D. Schreiber. "A new autologous fibrinogen-based adhesive for otologic surgery." Ann Otol Rhinol Laryngol 95 (1 Pt 1 1986): 40-5.
47 Fibrostik(TM) Plasma Concentrator, Attention Operating Surgeon, Cell Factor Technologies, Inc., Jul. 2003.
48 Fibrostik™ Plasma Concentrator, Attention Operating Surgeon, Cell Factor Technologies, Inc., Jul. 2003.
49 First clinical results: Kuderma, H. and Helene Matras. "Die klinische Anwendung der Klebung van Nervenanastomosen mit Gerinnungssubstanzen bei der Rekonstruction verletzter peripherer Nerven." Wein Klin Wochenschr 87 (15 1975): 495-501.
50 Floryan, K. et al. "Home Study Program: Intraoperative Use of Autologous Platelet-Rich and Platelet-Poor Plasma for Orthopedic Surgery Patients" vol. 80, No. 4 (Oct. 2004) p. 667-674.
51 Frasier, John K., et al., "Plasticity of human adipose stem cells toward endothelial cells and cardiomyocytes," Nature Clinical Practice Cardiovascular Medicine, vol. 3, Supplement 1 (Mar. 2006) pp. S33-S37.
52 Friesen, M.D., Robert, et al. "Blood Conservation During Pediatric Cardiac Surgery: Ultrafiltration of the Extracorporeal Circuit Volume After Cardiopulmonary Bypass." Anesth. Analg 1993: 77-702-7.
53 Galois, et al., "Cartilage Tissue Engineering: State-of-the-Art and Future Approaches," Pathol Biol (Paris), 53(10), Dec. 2005.
54 Gibble, J. W. and P. M. Ness. "Fibrin glue: the perfect operative sealant?" Transfusion 30 (8 1990): 741-7.
55 Gimble, Jeffrey M., "Adipose-Derived Stem Cells for Regenerative Medicine," Circulation Research (2007) pp. 1249-1260, American Heart Association, Inc.
56 Gomillion, Cheryl T., et al., "Stem cells and adipose tissue engineering," Biomaterials 27, Science Direct (2006) pp. 6052-6063, Elsevier.
57 GPS® II System, Gravitational Platelet Separation System, "Accelerating the Body's Natural Healing Process," Biomet Biologics (Jul. 15, 2006) 16 pages.
58 GPS® II System, Gravitational Platelet Separation System, "Accelerating the Body's Natural Healing Process," Cell Factor Technologies, Inc., Biomet Europe (2005) 16 pages, http://www.cellfactortech.com/global-products.cfm, printed Sep. 16, 2005.
59 GPS® II System, Gravitational Platelet Separation System, "Accelerating the Body's Natural Healing Process," Cell Factor Technologies, Inc., Biomet Europe (2005) 16 pages, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005.
60 GPS® II System, Gravitational Platelet Separation System, "User Manual," Cell Factor Technologies, Inc., Biomet Europe [date unknown] 13 pages, http://www.cellfactortech.com/global-products.cfm, printed Sep. 16, 2005.
61 GPS® II System, Gravitational Platelet Separation System, "User Manual," Cell Factor Technologies, Inc., Biomet Europe [date unknown] 13 pages, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005.
62 GPS® III System, GPS® III Platelet Separation System, Leadership through Technology, brochure, Jul. 2007 (8 sheets).
63 GPS® System, "GPS® Platelet Concentrate System," Cell Factor Technologies, Inc, Biomet Orthopaedics, Inc., (2004) (9 pages).
64 GPS® System, "Shoulder Recovery with the GPS® Platelet Concentrate System, Rotator Cuff Surgical Techniques," brochure, Cell Factor Technologies, Inc., Biomet Orthopaedics, Inc., (2004) 6 pages.
65 GPS® System, "Shoulder Recovery with the GPS® Platelet Concentrate System, Rotator Cuff Surgical Techniques," Cell Factor Technologies, Inc., Biomet Orthopaedics, Inc., (2004) 3 pages, http://www.cellfactortech.com/global-products.cfm, printed Sep. 16, 2005.
66 GPS® System, "Shoulder Recovery with the GPS® Platelet Concentrate System, Rotator Cuff Surgical Techniques," Cell Factor Technologies, Inc., Biomet Orthopaedics, Inc., (2004) 3 pages, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005.
67 Grove, et al., "Plasticity of Bone Marrow-Derived Stem Cells," Stem Cells: Concise Review, Jan. 22, 2004.
68 Guilak, Frank, et al., "Adipose-derived adult stem cells for cartilage tissue engineering," Biorheology 41 (2004) pp. 389-399, IOS Press.
69 Harris, E.L.V. Concentration of the Extract. In. Protein Purification Methods: A Practical Approach Harris, E.L.V.; Angal, S.; Editors. (1989) Publisher: (IRL Press, Oxford, UK), pp. 67-69.
70 Hartman, A. R., D. K. Galanakis, M. P. Honig, F. C. Seifert, and C. E. Anagnostopoulos. "Autologous whole plasma fibrin gel. Intraoperative procurement." Arch Surg 127 (Mar. 1992): 357-9.
71 Harvest SmartPrep PRP-20 Procedure Pack, "Instructions for Use".
72 Harvest Technologies brochure, SmartPrep2 (2002).
73 Hattori, et al., "Osteogenic Potential of Human Adipose Tissue-Derived Stromal Cells as an Alternative Stem Cell Source," Cells Tissues Organs (2004) 178:2-12 Karger.
74 Haynesworth, S.E. et al. "Mitogenic Stimulation of Human Mesenchymal Stem Cells by Platelet Releasate Suggests a Mechanism for Enhancement of Bone Repair by Platelet Concentrate" 48th Annual Meeting of the Orthopaedic Research Society Poster No. 0462 (2002).
75 Hennis, H. L., W. C. Stewart, and E. K. Jeter. "Infectious disease risks of fibrin glue [letter]." Ophthalmic Surg 23 (Sep. 1992): 640.
76 Hernigou, et al., "Percutaneous Autologous Bone-Marrow Grafting for Nonunions. Influence of the Number and Concentration of Progenitor Cells," Journal of Bone & Joint Surgery, 87-A(7):1430-1437 (Jul. 2005).
77 Hom, D., et al. "Promoting Healing with Recombinant Human Platelet-Derived Growth Factor-BB in a Previously Irradiated Problem Wound." The Laryngoscope, vol. 113 (pp. 1566-1671) Sep. 2003.
78 Hood, Andrew G., et al., "Perioperative Autologous Sequestration III: A New Physiologic Glue with Wound Healing Properties," (Jan. 1993) vol. 14 pp. 126-129.
79 International Preliminary Examination Report and Written Opinion issued Aug. 31, 2010 for PCT/US2009/035564 claiming benefit of U.S. Appl. No. 61/078,178, filed Jul. 3, 2008 of which U.S. Appl. No. 12/395,085, filed Feb. 27, 2009 claims benefit.
80 International Preliminary Examination Report and Written Opinion issued Aug. 31, 2010 for PCT/US2009/035564 claiming benefit of U.S. Appl. No. 61/078,178, filed Jul. 3, 2008, which priority is also claimed of said provisional case by U.S. Appl. No. 12/395,085, filed Feb. 27, 2009.
81 International Preliminary Report on Patentability and Written Opinion mailed Oct. 13, 2011 for PCT/US2010/029957 which claims benefit of U.S. Appl. No. 12/417,789, filed Apr. 3, 2009.
82 International Preliminary Report on Patentability completed Aug. 13, 2009 for PCT/US2008/004687 claiming benefit of U.S. Appl. No. 60/911,407, filed Apr. 12, 2007.
83 International Preliminary Report on Patentability mailed Feb. 12, 2009, for PCT/US2007/017055 filed Jul. 31, 2007, which claims benefit of U.S. Appl. No. 60/834,550, filed Jul. 31, 2006, based on U.S. Appl. No. 60/723,312, filed Oct. 4, 2005; U.S. Appl. No. 60/654,718, filed Feb. 17, 2005; and U.S. Appl. No. 60/651,050, filed Feb. 7, 2005.
84 International Preliminary Report on Patentability mailed Jan. 26, 2012 for PCT/US2010/041942 claiming benefit of U.S. Appl. No. 12/504,413, filed Jul. 16, 2009.
85 International Search Report and Written Opinion for PCT/US2006/003597 mailed Feb. 6, 2006.
86 International Search Report and Written Opinion for PCT/US2006/003599 mailed Aug. 21, 2006.
87 International Search Report and Written Opinion mailed Aug. 12, 2008 for PCT/US07/17055.
90 International Search Report and Written Opinion mailed Jul. 3, 2009 for PCT/US2009/035564 claiming benefit of U.S. Appl. 61/078,178, filed Jul. 3, 2008.
101 Journal of Biomaterials Applications, vol. 7, pp. 309-353, Apr. 1993, David H. Sierra, "Fibrin Sealant Adhesive Systems: A review of their Chemistry, Material Properties and Clinical Appllications".
102 Journal of Oral Maxillofacial Surgery, vol. 43, pp. 605-611, 1985, Helene Matras, M.D., "Fibrin Seal: The State of the Art".
103 Karpatkin, S., "Heterogeneity of Human Platelets. VI., Correlation of Platelet Function with Platelet Volume", Blood, vol. 51, No. 2 (Feb. 1978).
104 Kjaergard, H. K,, U. S. Weis-Fogh, H. Sorensen, J. Thiis, and I. Rygg. "A simple method of preparation o£ autologous fibrin glue by means of ethanol." Surg Gynecol Obstet 175 (Jan. 1992): 72-3.
105 Kjaergard, H. K., Fogh Us Weis, and J. J. Thiis. "Preparation of autologous fibrin glue from pericardial blood." Ann Thorac Sur 55 (Feb. 1993): 543-4.
106 Kumar, Vijay et al. "Stability of Human Thrombin Produced From 11 ml of Plasma Using the Thrombin Processing Device," Journal of American Society of Extra-Corporeal Technology. JECT: Mar. 2005:37; 390-395.
107 Kumar, Vijay et al. "Whole Blood Thrombin: Development of a Process for Intra-Operative Production of Human Thrombin." Journal of American Society of Extra-Corporeal Technology. JECT: Apr. 2007; 39:18-23.
108 Kumar, Vijay et al., "Autologous Thrombin: Intraoperative Production From Whole Blood." Journal of American Society of Extra-Corporeal Technology. JECT: Apr. 2008; 40:94-98.
109 Laryngoscope vol. 99, pp. 974-976, Sep. 1989, Kyosti Laitakari, M.D., et al., "Autologous and Homologous Fibrinogen Sealants: Adhesive Strength".
110 Laryngoscope, vol. 95, pp. 1074-1076, Sep. 1985, Karl H. Siedentop, M.D., et al., "Autologous Fibrin Tissue Adhesive".
111 Laryngoscope, vol. 96, pp. 1062-1064, Oct. 1986, Karl H. Siedentop, M.D., et al., "Extended Experimental and Preliminary Surgical Findings with Autologous Fibrin Tissue Adhesive Made from Patient's Own Blood".
112 Lasher, Lisa, M.D., "My Experience with PRP," PowerPoint presentation, http://www.cellfactortech.com/global-products.cfm, printed Sep. 16, 2005.
113 Lasher, Lisa, M.D., "My Experience with PRP," PowerPoint presentation, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005.
114 Lemer, R. and N. S. Binur. "Current status of surgical adhesives." J Surg Res 48 (Feb. 1990): 165-81.
115 Lendeckel, Stefan, et al., "Autologous stem cells (adipose) and fibrin glue used to treat widespread traumatic calvarial defects: case report," Journal of Cranio-Maxillofacial Surgery (2004) European Association for Cranio-Maxillofacial Surgery.
116 Longas, Maria O., "An Improved Method for the Purification of Human Fibrinogen." J. Biochem (1980) vol. 11, pp. 559-564.
117 Lu, et al., "Bone Marrow Mesenchymal Stem Cells: Progress in Bone/Cartilage Defect Repair," 19(1), Jan. 2002.
118 Marrowstim Concentration System, Biomet Biologics, Inc., 20 pages (REV Feb. 15, 2008).
119 Marrowstim™ Concentration System, (2008) 20 pages Biomet Biologics, Inc.
120 Marx, Gerard, et al., "Heat Denaturation of Fibrinogen to Develop a Biomedical Matrix." Journal of Biomedical Materials Research Part B: Applied Biomaterials (Apr. 2007) pp. 49-57.
121 Masri, Marwan A., et al. "Isolation of Human Fibrinogen of High Purity and in High Yield Using Polyethylene Glycol 1000." Thromb Haemostas (Struttgart) (1983) vol. 49 (2); pp. 116-119.
122 Matras, Helene, H. P. Dinges, H. Lassmann, and B. Mamoli. "Zur nahtlosen interfaszikularen Nerventransplantation im Tierexperiment." Wein Med Woschtr 122 (37 1972): 517-523.
123 Minntech® Filtration Technologies Group, "Hemocor HPH® Hemoconcentrator," Minntech Corporation (2004); http://www.minntech.com/ftg/products/hph/index.html, printed Jul. 15, 2004 (2 pages).
124 Minntech® Filtration Technologies Group, "Medical Applications: Blood Filtration" Minntech Corporation (2004); http://www.minntech.com/ftg/industries/medical/blood—filter.html, printed Jul. 15, 2004 (1 page).
125 Minntech® Filtration Technologies Group, "Renaflo® II Hemofilter," Minntech Corporation (2004); http://www.minntech.com/ftg/products/renaflo/index.html, printed Jul. 15, 2004 (2 pages).
126 Molnar, Amy, "Stem Cells from Muscles Can Repair Cartilage, Study Finds Genetically Engineered Muscle-Derived Stem Cells Improved Cartilage Repair in Rats", American College of Rheumatology, (2005).
127 Moretz, W., Jr., J Shea Jr., J. R. Emmett, and J Shea. "A simple autologous fibrinogen glue for otologic surgery." Otolaryngol Head Neck Surg 95 (Jan. 1986): 122-4.
128 Nakagami, Hironori, et al., "Novel Autologous Cell Tehrapy in Ischemic Limb Disease Through Growth Factor Secretion by Cultured Adipose Tissue-Derived Stromal Cells," Angiogenesis by Adipose Tissue-Derived Cells, (2005) pp. 2542-2547, American Heart Association, Inc.
129 Nathan, Suresh et al., "Cell-Based Therapy in the Repair of Osteochondral Defects: A Novel Use for Adipose Tissue," Tissue Engineering, vol. 9, No. 4 (2003) pp. 733-744 Mary Ann Liebert, Inc.
130 Nilsson, et al., "Bone Repair Induced by Bone Morphogenetic Protein in Ulnar Defects in Dogs," The Journal of Bone and Joint Surgery, vol. 68 B., No. 4, Aug. 1986.
131 Office Action mailed Apr. 6, 2010 for Japanese Application No. 2007554191 filed Aug. 7, 2007 has been provided including a partial translation thereof, which also cites JP2001017540. Japanese Application No. 2007554191 claims benefit of PCT/US2006/003597, filed Jan. 30, 2006; claiming priority from U.S. Appl. No. 60/651,050, filed Feb. 7, 2005; U.S. Appl. No. 60/654,718, filed Feb. 17, 2005; and U.S. Appl. No. 60/723,312, filed Oct. 4, 2005 of which U.S. Appl. No. 11/831,605, filed Jul. 31, 2007 and U.S. Appl. No. 12/772,497, filed May 3, 2010 claim benefit.
132 Office Action mailed Apr. 6, 2010 for Japanese Application No. 2007-554193 filed Aug. 23, 2007 has been provided including a partial translation thereof, which cites JP11-502502 and JP2001017540. Japanese Application No. 2007-554193 claims benefit of PCT/US2006/003599, filed Jan. 30, 2006; claiming priority from U.S. Appl. No. 60/651,050, filed Feb. 7, 2005; U.S. Appl. No. 60/654,718, filed Feb. 17, 2005; and U.S. Appl. No. 60/723,312, filed Oct. 4, 2005 of which U.S. Appl. No. 11/831,605 filed Jul. 31, 2007 and U.S. Appl. No. 12/772,497, filed May 3, 2010 claim benefit.
133 Office Action mailed Sep. 14, 2010 for Japanese Application No. 2007554191 filed Aug. 7, 2007 has been provided including a partial translation thereof. Japanese Application No. 2007554191 claims benefit of PCT/US2006/003597, filed Jan. 30, 2006; claiming priority from U.S. Appl. No. 60/651,050, filed Feb. 7, 2005; U.S. Appl. No. 60/654,718, filed Feb. 17, 2005; and U.S. Appl. No. 60/723,312, filed Oct. 4, 2005 of which U.S. Appl. No. 11/831,605, filed Jul. 31, 2007 and U.S. Appl. No. 12/772,497, filed May 3, 2010 claim benefit.
134 Office Action mailed Sep. 14, 2010 for Japanese Application No. 2007-554193 filed Aug. 23, 2007 has been provided including a partial translation thereof. Japanese Application No. 2007-554193 claims benefit of PCT/US2006/003599, filed Jan. 30, 2006; claiming priority from U.S. Appl. No. 60/651,050, filed Feb. 7, 2005; U.S. Appl. No. 60/654,718, filed Feb. 17, 2005; and U.S. Appl. No. 60/723,312, filed Oct. 4, 2005 of which U.S. Appl. No. 11/831,605, filed Jul. 31, 2007 and U.S. Appl. No. 12/772,497, filed May 3, 2010 claim benefit.
135 Orphardt, Charles E., "Denaturation of Proteins," Virtual Chembook, Elmhurst College (2003) 3 pages. http://www.elmhurst.edu/~chm/vchembook/568denaturation.html (web accessed Mar. 9, 2011).
136 Orphardt, Charles E., "Denaturation of Proteins," Virtual Chembook, Elmhurst College (2003) 3 pages. http://www.elmhurst.edu/˜chm/vchembook/568denaturation.html (web accessed Mar. 9, 2011).
137 Otolaryngologic Clinics of North America, vol. 27, No. 1, pp. 203-209, Feb. 1994, Dean M. Toriumi, M.D., et al., "Surgical Tissue Adhesives in Otolaryngology—Head and Neck Surgery".
138 Parker, Anna M., et al., Adipose-derived stem cells for the regeneration of damaged tissues, Expert Opinion, Cell- & Tissue-based Therapy, Expert Opin. Biol. Ther. (2006) pp. 567-578 Informa UK Ltd.
139 Planat-Bénard, V., et al., "Spontaneous Cardiomyocyte Differentiation From Adipose Tissue Stroma Cells," Adipose-Derived Cell Cardiomyocyte (2004) pp. 223-229 American Heart Association, Inc.
140 Plasmax™ Plasma Concentrate, brochure (2006) 5 pages Biomet Biologics, Inc.
141 Ponticiello, Michael S., "A Rapid Technique for the Isolation and Concentration of Stem Cells from Human Bone Marrow", Cell Factor Technologies, Inc. (undated) 1 page.
142 Rangappa, Sunil, M.D., "Transformation of Adult Mesenchymal Stem Cells Isolated From the Fatty Tissue Into Cardiomyocytes," Adult Stem Cells Transformed into Cardiomyoctyes, (2003) pp. 775-779 Ann Thorac Surg.
143 Rigotti, M.D., et al, "Clinical Treatment of Radiotherapy Tissue Damage by Lipoaspirate Transplant: A Healing Process Mediated by Adipose-Derived Adult Stem Cells," Plastic and Reconstructive Surgery, Breast, PRS Journal vol. 119, No. 5, Stem Cell Therapy for Angiogenesis, (Apr. 15, 2007) pp. 1409-1422.
144 Rigotti, M.D., et al, "Clinical Treatment of Radiotherapy Tissue Damage by Lipoaspirate Transplant: A Healing Process Mediated by Adipose-Derived Adult Stem Cells," Plastic and Reconstructive Surgery, Breast, PRS Journal vol. 119, No. 5, Stem Cell Therapy for Angiogenesis, (Pub. 2005) pp. 1409-1422.
145 Rubin, M.D., et al, "Clinical Treatment of Radiotherapy Tissue Damage by Lipoaspirate Transplant: A Healing Process Mediated by Adipose-Derived Adult Stem Cells," Plastic and Reconstructive Surgery, Discussion vol. 119, No. 5, Stem Cell Therapy for Angiogenesis, (2007) pp. 1423-1424.
146 Sanal, M. "Does fibrin glue cause foreign body reactions? [letter]." Eur J Pediatr Surg 3 (1992): 190 (1 page).
147 Sanal, M. "Does fibrin glue cause foreign body reactions? [letter]." Eur J Pediatr Surg 3 (Mar. 1993): 190 (1 page).
148 Sanal, M., H. Dogruyol, A. Gurpinar, and O. Yerci. "Does fibrin glue cause foreign body reactions?" Eu r J Pediatr Surg 2 (May 1992): 285-6.
149 Schäffler, Andreas, et al., "Concise Review: Adipose Tissue-Derived Stromal Cells—Basic and Clinical Implications for Novel Cell-Based Therapies," Tissue-Specific Stem Cells, Stem Cells® (2007) pp. 818-827 AlphaMed Press.
150 Schmidt, K.G., et al., "Labelling of Human and Rabbit Platelets with Indium-Oxine Complex", 23:97-106 (1979).
151 Schmidt, K.G., et al., "Preparation of Platelet Suspensions from Whole Blood in Buffer", Scand. J. Hoemato, 23:88-96 (1979).
152 Semple, Elizabeth, PhD, et al. "Quality of Thrombin Produced From the Patient's Own Plasma Using the TPD™, a New Thrombin-Processing Device." Journal of American Society of Extra-Corporeal Technology. JECT: 2005; 37:196-200.
153 Sierra, D. H. "Fibrin sealant adhesive systems: a review of their chemistry, material properties and clinical applications." J Biomater Appl 7 (Apr. 1993): 309-52.
154 Sigma-Aldrich® Alkaline Phosphatase (Procedure No. 85), drug fact sheet, (2003) pp. 1-2, Sigma-Aldrich, Inc.
155 Silver, Frederick H., et al., "Review Preparation and use of fibrin glue in surgery." Biomaterials 16 (1995) pp. 891-903.
156 Solem, Jan Otto, et al., "Hemoconcentration by Ultrafiltration During Open-Heart Surgery," Scand J Thor Cardiovasc Surg 22:271-274, 1988.
157 Sutton, Robin G., et al. "Comparison of Three Blood-Processing Techniques During and After Cardiopulmonary Bypass." Ann Thorac Surg (1993) vol. 56; pp. 941-943.
158 Swift, Mathew J., et al., "Characterization of Growth Factors in Platelet Rich Plasma," 1-Cell Factor Technologies, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005.
159 Symphony II Platelet Concentrate System/PCS brochure; "Increasing bone graft bioactivity through reproducible concentrations of natural growth factors," DePuy (Jan. 2003).
160 Takahashi, Kazutoshi et al., "Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors," Cell, (2007) pp. 1-12, Elsevier Inc.
161 The American Journal of Surgery, vol. 168, pp. 120-122, Aug. 1994, Roy L. Tawes, Jr., M.D., et al., "Autologous Fibrin Glue: The Last Step in Operative Hemostatis".
162 The American Surgeon, vol. 55, pp. 166-168, Mar. 1989, William D. Spotnitz, M.D., et al., "Successful Use of Fibrin Glue During 2 Years of Surgery at a University Medical Center".
163 The Sports Medicine Center, "Knee Cartilage Implantation", Carticel™, "Autologous Cultured Chondrocyte Implantation", http://www.orthoassociates.com/carticel.htm (printed Apr. 6, 2006).
164 The Stone Clinic, "Platelet Rich Plasma (PRP)", web site printed May 2006.
165 Vortech™ Concentration System, "Do you want a sticky gel to improve the handling of your bone graft?, Platelet Rich Plasma Concentrate, High Volume in 5 Minutes," Biomet Biologics, Inc., Aug. 2005.
166 Vox Sanquinis, vol. 68: 82-89, Feb. 1995, Boomgaard Et. al, Pooled Platelet Concentration Prepred by the . . . .
167 Weis-Fogh, U. S. "Fibrinogen prepared from small blood samples for autologous use in a tissue adhesive system." Eur Surg Res 20 (May-Jun. 1988): 381-9.
168 Weisman, MD., Robert A., "Biochemical Characterization of Autologous Fibrinogen Adhesive," Laryngoscope 97: Oct. 1987; pp. 1186-1190.
169 Wiseman, David M., David T. Rovee, and Oscar M. Alverez. "Wound Dressings: Design and Use." In Wound Healing: Biochemical & Clinical Aspects,ed. I. Kelman Cohen, Robert F. Diegelmann, and William J. Lindblad. 562-580. 1st ed., vol. Philadelphia: W. B. Saunders Company, 1992).
170 Woodell-May, et al., "Producing Accurate Platelet Counts for Platelet Rich Plasma: Validation of a Hematology Analyzer and Preparation Techniques for Counting," Scientific Foundation, Journal of Carniofacial Surgery 16(5):749-756 (Sep. 2005).
171 Written Opinion of the International Preliminary Examining Authority mailed Mar. 17, 2009 for International Application No. PCT/US2008/004687 which claims priority to U.S. Appl. No. 60/911,407, filed Apr. 12, 2007.
172 Yoon, Eulsik, M.D., Ph.D., et al., "In Vivo Osteogenic Potential of Human Adipose-Derived Stem Cells/Poly Lactide-Co-Glycolic Acid Constructs for Bone Regneration in a Rat Critical-Sized Calvarial Defect Model," Tissue Engineering, vol. 13, No. 3 (2007) pp. 619-627 Mary Ann Liebert, Inc.
173 Zhang, Duan-zhen, et al., "Transplantation of autologous adipose-derived stem cells ameliorates cardiac function in rabbits with myocardial infarction," Chinese Medical Journal, vol. 120, No. 4 (2007) pp. 300-307 General Hospital of Shenyang Military Region, Shenyang, China.
174 Zuk, Patricia A., Ph.D., "Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based Therapies," Tissue Engineering, vol. 7, No. 2, (2001) pp. 211-228 Mary Ann Liebert, Inc.
US9719063 * 11 Ago 2014 1 Ago 2017 Biomet Biologics, Llc System and process for separating a material
US9770743 * 1 Ago 2014 26 Sep 2017 Regenesis Bioremediation Products Colloidal agents for aquifer remediation
US20140349388 * 11 Ago 2014 27 Nov 2014 Biomet Biologics, Llc System And Process For Separating A Material
US20150034559 * 1 Ago 2014 5 Feb 2015 Regenesis Bioremediation Products Colloidal agents for aquifer remediation
Clasificación de EE.UU. 210/782, 604/6.01, 210/360.1, 210/789, 604/403, 210/380.1, 604/6.15, 422/72, 422/527, 210/516
Clasificación internacional B01D21/26, B04B3/00
Clasificación cooperativa G01N1/4077, G01N1/286, B01L2200/026, B01L3/5635, B01L3/5021, B01L3/50825, C12M47/02, C12M47/04, B01L2300/046
Clasificación europea B01L3/5021, G01N1/40V, G01N1/28M